Information Note: New Fair Share Funding Targets for TB Research 0.1% -> 0.15%
In 2017 Treatment Action Group and partners introduced the “fair share” funding targets for TB research.
2022 Report on TB Research Funding Trends
For the first time in history, funding for tuberculosis (TB) research and development (R&D) hit a billion dollars worldwide in 2021.
European Commitments to TB R&D Investments: Promises Made to Be Broken?
In this brief, TAG outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.
TB Vaccine Advocacy Roadmap Calls for Increased EU Funding for TB Vaccine Development
TAG stands proudly alongside the TB community to issue this press statement calling for increasing European funding for TB vaccine development, just before the sixth Global Forum on TB Vaccines convenes in Toulouse, France.
2021 Report on TB Research Funding Trends
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2020 and analyzes trends in funding since 2005.
2020 Report on TB Research Funding Trends
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2019 and analyzes trends in funding since 2005.
2019 Report on TB Research Funding Trends
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2018 and analyzes trends in funding since 2005.
Closing the Gap in Tuberculosis Research and Development Funding Briefs
In our two briefs, Closing the Gap in Tuberculosis Research and Development Funding: Actions for U.S. Government Executive Agencies and Actions for U.S. Congress, we detail how a funding increase of 0.1 percent, based on "fair share" of research capacity, would close the funding gap in TB R&D, catalyze new public health tools we need to create positive health outcomes among communities vulnerable to TB worldwide.
Rapid Shift From Global To National Purchase of TB Drugs Increases Risk of Stockouts and Use of Drugs of Unknown Quality
Global activists at the 49th Union Conference on Lung Health in The Hague opened up a pop-up TB drug warehouse to warn about the dire public health consequences of a rushed shift from Global Fund supported pooled procurement of tuberculosis (TB) drugs and other health products to domestic funding and national procurement systems.
Higher Funding for TB Research Signals Hope, but Governments Must Dramatically Increase Spending to End TB
Global funding for tuberculosis (TB) research reached a previously unreported high of $726 million in 2016, according to a report released today by Treatment Action Group (TAG) and the United Nations–hosted Stop TB Partnership.